Creative Biolabs is a leading service company with years of experience in autoimmune disease research and drug development, making us an excellent global customer choice. Currently, we offer custom drug development services for autoimmune diseases, such as microscopic polyangiitis (MPA), to meet your specific demands.
MPA is an idiopathic autoimmune disease characterized by systemic vasculitis. The disease is a family member of antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitides (AAV), and ANCA can be detected in 80% of affected patients. Its characteristic histology shows a necrotizing small-vessel vasculitis with little or absent immune deposits (pauci-immune vasculitis), primarily affecting small vessels, including arterioles and venules or capillaries. While cutaneous, gastrointestinal, musculoskeletal, and neurological manifestations can be observed in MPA, the most typical clinical manifestations may consist of glomerulonephritis and pulmonary hemorrhage. Pulmonary fibrosis is also a potentially severe MPA manifestation, and mild pulmonary fibrosis is significantly associated with an increased mortality rate.
Given that most MPA patients will present with glomerulonephritis, initial therapy of MPA generally entails glucocorticoids and immunosuppressant(s), usually cyclophosphamide. In this setting, even though MPA outcomes are effectively improved with cyclophosphamide, this regimen is associated with substantial toxicity, which produces significant morbidity and mortality. Therefore, investigators have focused on developing strategies to treat MPA that avoid using cytotoxic agents altogether.
There is an FDA-approved antibody drug that represents an essential alternative to cyclophosphamide for patients who may not respond adequately to antimetabolite therapies. The rationale for using this antibody drug in MPA stems from the central role played by B cells in the pathogenesis of these diseases. This antibody drug has reportedly achieved significant remission of MPA in patients with severe and/or refractory diseases, with an excellent global safety profile. Besides, a better understanding of the pathogenesis of MPA has led to the investigation of therapies that target B cells. Therapies targeting the cells that produce these antibodies (short-lived plasma cells of B-cell origin) and other functions of B cells, such as antigen presentation and cytokine release, have been considered as potential treatments for MPA.
Fig.1 Treatment strategies for MPA. (Greco, 2015)
The future of MPA treatment seems bright, as some newer medications and therapies show great promise as effective alternative therapeutic agents with potentially less toxicity. Creative Biolabs is a leading service company with a robust and standardized platform supporting MPA research and drug development. With over a decade of experience and state-of-the-art drug development platforms, a specialized and dedicated team at Creative Biolabs offers a full range of highly custom drug development solutions to support your therapeutics development requirement effectively. We provide you with the best services, including but not limited to:
Creative Biolabs is a dedicated provider that strives to offer the highest quality MPA drug development services for our customers worldwide. We are pleased to provide support for any of your questions. Please ask an expert for a specific consultation on your project.
For Research Use Only | Not For Clinical Use